A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer With RS</=25 (RxFINE-Low)
Latest Information Update: 11 Feb 2026
At a glance
- Drugs Anastrozole (Primary) ; Exemestane (Primary) ; Letrozole (Primary) ; Ribociclib (Primary)
- Indications Breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms RxFINE-Low
Most Recent Events
- 11 Feb 2026 New trial record